Latest News and Press Releases

EMERYVILLE, Calif., May 08, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new...

First quarter 2020 GOCOVRI® product sales of $14.5 million, a 24% increase over first quarter 2019 Total paid prescriptions grew approximately 24% to 7,210 over first quarter 2019 EMERYVILLE,...

EMERYVILLE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May...

EMERYVILLE, Calif., April 10, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven...

EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new...

- Full year 2019 GOCOVRI® product sales of $54.6 million, a 60% increase over 2018;total paid prescriptions grew approximately 66% to 25,780 - Fourth quarter 2019 GOCOVRI® product sales of $16.3...

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...

EMERYVILLE, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday,...

EMERYVILLE, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful...

-  Final results reported from the longest-running clinical trial of an amantadine product in Parkinson’s disease - Patients taking GOCOVRI experienced long-term reductions in both dyskinesia and OFF...